ALGS
Aligos·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
Significant Net Income Decline
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ALGS
Aligos Therapeutics, Inc.
A clinical stage biopharmaceutical company that developing therapeutics for viral and liver diseases
One Corporate Drive, 2nd Floor, South San Francisco, California 94080
--
Aligos Therapeutics, Inc., was incorporated in Delaware on February 5, 2018. The company is a clinical-stage biopharmaceutical company focused on developing novel therapies to address unmet medical needs in liver disease and viral infections.
Company Financials
EPS
ALGS has released its 2025 Q3 earnings. EPS was reported at -3.04, versus the expected -2.01, missing expectations. The chart below visualizes how ALGS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ALGS has released its 2025 Q3 earnings report, with revenue of 741.00K, reflecting a YoY change of -41.61%, and net profit of -31.54M, showing a YoY change of -63.75%. The Sankey diagram below clearly presents ALGS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
